Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeo Medical Inc.

This article was originally published in Start Up

Executive Summary

The founders of Valeo Medical believe that endometriosis, a leading cause of infertility in the US, is a type of auto-immune disorder. Based on this premise, Valeo is developing an endometriosis diagnostic by searching for auto-antibodies to a variety of carbohydrate antigens in serum samples. The company believes the market opportunity is great, because there is no non-invasive diagnostic for endometriosis.

You may also be interested in...



Women's Health: A Growing Market for Diagnostic Players

Women's health is an area long shunned by pharmaceutical and diagnostic companies. But that is starting to change thanks to the successes of companies such as Cytyc and Digene, who have built successful testing franchises in the Ob/ Gyn market. As companies such as PerkinElmer and others look to develop new tests in this market, a spate of start-ups are developing technologies that might fit the bill. Of greatest interest are the so-called molecular tests since they offer the advantage of premium pricing.

Performance Issues With CDC’s COVID-19 Assay Reagent Slows Rollout Of Test Kits To US States

A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel